Hipersensibilidad a Betalactámicos. Dra Yurlany Gutiérrez (20 de septiembre 2018)

De


Hipersensibilidad a Betalactámicos.  Dra Yurlany Gutiérrez (20 de septiembre 2018)

Comentarios

  1. Ricardo Cardona Villa21 de septiembre de 2018, 9:39

    Artículo recomendado:

    Cross-reactivity in b-Lactam Allergy
    Robert J. Zagursky, PhD, and Michael E. Pichichero, MD Rochester, NY

    b-Lactam drugs (penicillins, amoxicillin, and cephalosporins)
    account for 42.6% of all severe drug-induced anaphylaxis. In this
    review, we focus on clinically significant immunologic crossreactivity
    in patients with confirmed penicillin allergy to
    cephalosporins, and the structural involvement of the R1 and R2
    chemical side chains of the cephalosporins causing IgE-mediated
    cross-reactivity with penicillin and other cephalosporins. Skin
    tests predict IgE-mediated reactions and showed cross-reactivity
    between penicillins and early generation cephalosporins that
    shared side chains, but confirmatory challenge data are lacking.
    Later-generation cephalosporins, which have distinct side chains,
    do not have any skin test cross-reactivity with penicillin/
    amoxicillin. There is debate as to the involvement of R2 side
    chains as the antigenic determinants that cause IgE-mediated
    hypersensitivity with various cephalosporins. Avoidance of
    cephalosporins, when they are the drug of choice in a penicillinallergic individual, results in significant morbidity that outweighs the low risk of anaphylaxis. We conclude that there is ample evidence to allow the safe use of cephalosporins in patients with isolated confirmed penicillin or amoxicillinallergy.

    Texto completo:
    http://dx.doi.org/10.1016/j.jaip.2017.08.027

    ResponderEliminar

Publicar un comentario

Entradas populares de este blog

La biopsia cutánea en la urticaria crónica: cuándo realizarla, qué buscar y dónde hacerlo

De
La biopsia cutánea en la urticaria crónica: cuándo realizarla, qué buscar y dónde hacerlo Autores: A. López Mateos, M.J. Sánchez Pujol y J.F. Silvestre Salvador Resumen: La urticaria crónica es una entidad relativamente frecuente en la práctica clínica habitual, cuyo diagnóstico se establece de forma clínica. Sin embargo, existen ocasiones en las que está indicada la realización de una biopsia cutánea para confirmar el diagnóstico y diferenciarla de otras patologías que pueden cursar con erupciones urticariformes. En este trabajo revisamos los hallazgos histopatológicos que podemos encontrar tanto en la urticaria crónica como en las patologías que plantean un diagnóstico diferencial. Con base en ello, proponemos un algoritmo que recoge las indicaciones para realizar una biopsia cutánea y la orientación del diagnóstico en función de los hallazgos histopatológicos que encontremos en la misma. DOI:   https://doi.org/10.1016/j.ad.2020.11.016
Leer más

Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. Fecha: Miércoles 12 de junio

De
Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. Authors: Castells M1, Butterfield J2. 1 Division of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital Mastocytosis Center, Boston, Mass. Electronic address: mcastells@bwh.harvard.edu. 2 Mayo Clinic Program for Mast Cell and Eosinophil Disorders, Mayo Clinic, Rochester, Minn. Abstract: Patients with clonal mast cell activation syndromes (MCAS) including cutaneous and systemic mastocytosis (SM) may present with symptoms of mast cell activation, but in addition can have organ damage from the local effects of tissue infiltration by clonal mast cells. Patients with nonclonal MCAS may have chronic or episodic mast cell activation symptoms with an increase in serum tryptase and/or urinary metabolites of histamine, prostaglandin D2, and leukotrienes. Symptoms of MCAS and SM can be managed by blockade of mediator receptors (H1 and H2 antihistamines, leukotriene r...
Leer más

Skin bacterial transplant in atopic dermatitis: Knowns, unknowns and emerging trends. Miércoles 21 de agosto

De
Skin bacterial transplant in atopic dermatitis: Knowns, unknowns and emerging trends. Authors:  Hendricks AJ1, Mills BW2, Shi VY3. 1 University of Arizona College of Medicine, Tucson, AZ USA. 2 Texas Tech Health Sciences Center El Paso Paul L. Foster School of Medicine, El Paso, TX USA. 3 University of Arizona Department of Medicine, Division of Dermatology, Tucson, AZ USA. Electronic address: vshi@email.arizona.edu. Abstract: Dysbiosis is a key pathogenic factor in the cycle of  skin  barrier impairment and inflammation in  atopic   dermatitis  (AD).  Skin  microbial composition in AD is characterized by increased presence of Staphylococcus aureus (S. aureus) and decrease in microbial diversity and commensal  bacterial  species. Attenuation of S. aureus-driven inflammation aids in breaking the itch-scratch cycle via modulation of the cutaneous immune response.  Skin   bacterial   transplant  (SBT), a f...
Leer más